Donna Gustafson, a 72-year-old retired accountant, has become a notable case in cancer treatment after receiving an experimental mRNA vaccine designed specifically to combat her Stage II pancreatic cancer. The vaccine, developed using samples from her tumor, was designed to train her immune cells to recognize and eliminate cancerous cells. Seven years after receiving the treatment, Gustafson shows no evidence of the disease and maintains an active lifestyle that includes hiking, traveling, and weight training.
Gustafson was the first person to receive this personalized mRNA cancer vaccine, which was part of a clinical trial at Memorial Sloan Kettering Cancer Center in New York City led by surgeon and scientist Vinod Balachandran. The trial included 16 pancreatic cancer patients. Gustafson received nine doses of the vaccine along with surgery and chemotherapy. Of the trial participants, the vaccine was effective in half of the patients, and seven of those eight treated patients remain alive today.
The field of mRNA cancer vaccines has gained momentum recently. Last month, drugmakers Merck and Moderna released results from a major trial testing mRNA vaccines for skin cancer, demonstrating a 42% reduction in recurrence and death over two years. These vaccines combine mRNA technology, genomics, and artificial intelligence. Research is currently underway to test similar approaches against lung, kidney, bladder, and brain cancers. However, researchers acknowledge that they do not yet fully understand why some trials have failed while others show significant results.
The treatment offers practical advantages over traditional chemotherapy. Gustafson reported experiencing no symptoms or side effects from the vaccine shots, in stark contrast to the difficult side effects she experienced from chemotherapy. Laboratory analysis of her immune response showed a dramatic increase in cancer-fighting immune cells that was sustained for years after her final injection. The National Cancer Institute is now partnering with private companies to accelerate research and development of additional mRNA cancer vaccines, with plans to expand production capacity at major medical centers like Sloan Kettering.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI